Hot Features
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that ... Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.58 | -5.73122529644 | 10.12 | 10.157161 | 9.22 | 77372 | 9.61663937 | CS |
| 4 | -0.78 | -7.55813953488 | 10.32 | 13.34 | 9.22 | 117679 | 10.74221382 | CS |
| 12 | 0.36 | 3.92156862745 | 9.18 | 13.34 | 7.17 | 79302 | 9.6591254 | CS |
| 26 | 2.76 | 40.7079646018 | 6.78 | 13.34 | 6.47 | 72445 | 8.99602183 | CS |
| 52 | 0.55 | 6.11790878754 | 8.99 | 13.34 | 5.55 | 100279 | 7.70358454 | CS |
| 156 | -7.91 | -45.329512894 | 17.45 | 18.65 | 4.44 | 99490 | 8.20498293 | CS |
| 260 | 5.59 | 141.518987342 | 3.95 | 20.92 | 3.08 | 162109 | 7.86328512 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.